Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan plus FOLFOX in metastatic gastric cancer
NCT04358354Phase 3Unknown
- Sponsor
- The Sixth Affiliated Hospital of Sun Yat-Sen University
- Start
- Oct 2020
- Primary completion
- Dec 2023
- Modality
- Nanoparticles, Monoclonal Antibodies, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab in gastric cancer (GC) (2 arms), sponsored by The Sixth Affiliated Hospital of Sun Yat-Sen University. Primary endpoint: Overall Survival at 2 years. Status: unknown.
02
Drugs
irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT04358354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04358354.